[{"orgOrder":0,"company":"Pregene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-NK Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BCMA Nanobody CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"PRG1801","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pregene","sponsor":"Henan Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Henan Cancer Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Henan Cancer Hospital"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CAR19-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EGFR IL12 CART","moa":"EGFR \/ IL-12","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"EGFR CART","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"7","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Pregene","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-2311","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Chunrui Li","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Chunrui Li","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Chunrui Li"},{"orgOrder":0,"company":"Pregene","sponsor":"Lingli Dong","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Lingli Dong","highestDevelopmentStatusID":"1","companyTruncated":"Pregene \/ Lingli Dong"},{"orgOrder":0,"company":"Pregene","sponsor":"Tan Jie","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG2302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Tan Jie","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Tan Jie"},{"orgOrder":0,"company":"Pregene","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pregene","amount2":1.6399999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":1.6399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pregene \/ Kite Pharma"}]
Find Clinical Drug Pipeline Developments & Deals by Pregene
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
